Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026 Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Updates Scientific Presentations and Publications In March 2026, the results of our Phase 2b trial...

(All amounts in release are in Canadian dollars) OTTAWA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX:CGY), a mission critical solutions company focused on defence, space, healthcare and other strategic critical infrastructure sectors, today released its results for the second quarter ended March 31, 2026. “Our second quarter results mark an important inflection point for Calian as we begin to capture the benefits of strengthening demand across the defence sector,” said Patrick Houston, Calian CEO. “Revenue grew 18%, including 12% organic growth, which was achieved through record-setting deliveries and a strong pace of contract signings. This solid top-line performance translated into an 60% increase in adjusted EBITDA1, which significantly outpaced revenue growth and reflects the compounded...

Company Reaffirms Annual Guidance; New Product Innovation Supports Improving Sales Trends Exiting the Quarter GRAPEVINE, Texas, May 14, 2026 (GLOBE NEWSWIRE) — Solo Brands, Inc. (OTCQB: SBDS) (“Solo Brands” or “the Company”), a leading portfolio of lifestyle brands (Solo Stove, Chubbies, ISLE and Oru) that are redefining the outdoor and apparel industries, today announced its financial results for the three months ended March 31, 2026. “The first quarter reflects meaningful progress in our transformation as we operate Solo Brands with a leaner cost structure, stronger cash discipline, and a sharper focus on profitability,” said John Larson, President and Chief Executive Officer. “While top-line performance remained challenged, particularly within Solo Stove, the decisive actions we’ve taken over the past year have significantly...

SINGAPORE, May 14, 2026 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for AI and Bitcoin mining infrastructure, today released its unaudited financial results for the first quarter ended March 31, 2026. Q1 2026 Financial1 HighlightAll amounts compared to Q1’25 unless otherwise notedTotal revenue was US$188.9 million vs. US$70.1 million. Cost of revenue was US$228.0 million vs. US$74.1 million. Gross loss was US$39.0 million vs. US$4.0 million. Net loss was US$159.5 million vs. net profit of US$105.3 million. Adjusted EBITDA2 was positive US$14.4 million vs. negative US$45.6 million. Cash, cash equivalents and restricted cash were US$297.7 million as of March 31, 2026. Digital assets and digital assets – receivable balance: US$245.0 million as...

Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026 Cross-species nonclinical findings that support skin frataxin levels as a surrogate endpoint for nomlabofusp program published in peer-reviewed journalTopline open label study data to support BLA submission expected in Q2 2026 $200.4 million in cash, cash equivalents and marketable securities as of March 31, 2026, with projected cash runway into the second quarter of 2027BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2026...

Operational Highlights for the First Quarter of 2026Launched a non-radioactive, full-scale, at-depth demonstration of the Company’s deep borehole waste disposal technology at Halliburton’s Drilling Technology Facility near Cameron, TX Successfully completed work under the U.S. Department of Energy Advanced Research Projects Agency-Energy’s (“ARPA-E”) Optimizing Nuclear Waste and Advanced Reactor Disposal Systems (“ONWARDS”), a project led by Oklo, Inc. Selected to participate in ARPA-E’s SCALEUP Ready program, providing up to $20 million to accelerate market adoption of Deep Isolation’s deep borehole waste disposal technology and the first time a company in the nuclear industry has been selected to participate Appointed nuclear industry veteran Ralph L. Hunter to the board of directors on January 23, 2026, Appointed...

Company Reports Record $8.8M Net Income and $19.5M Adjusted EBITDA(8) Treasury Exceeds 2.00M HYPE, 1.92M KNTQ, & 10.00M HPL Tokens as of May 11(14) HYPD’s Unique “Triple-Dip” HYPE Deployment Generated >3x Base Staking Income in Q1 Company Raises Adjusted Gross Profit(1) 2026 FY Guidance by ~20% DALLAS, May 14, 2026 (GLOBE NEWSWIRE) — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today reported results for the first quarter ending March 31, 2026. “We are pleased to report continued scaling of our DeFi operating businesses, accretive balance sheet growth, and prudent cost management,” said Hyunsu Jung, CEO of Hyperion DeFi. Mr. Jung continued, “The opportunities to build on Hyperliquid are immense and expanding every day. More products...

MONTREAL, May 14, 2026 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the first quarter of fiscal 2026. Highlights Financial resultsHigher production and operating income in Q1-2026:Production up 12% (8% on a Combined1 basis)2 from Q1-2025, driven by new site commissioning and better wind conditions, and 1% (4%) below anticipated production;1 Operating income of $92 million ($103 million) in Q1-2026, up $27 million ($4 million) from Q1-2025; EBITDA(A)1 of $174 million ($207 million) in Q1-2026, down $2 million (up $8 million) from Q1-2025 owing mainly to a lower contribution from sites held as joint ventures, as well as to lower short-term power purchase agreement prices in France, both of which were almost entirely offset by the impact of new commissioning; Net...

Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a dose cap Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination with pembrolizumab in 1L R/M HNSCC on track for the second half of 2026 Presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 that support the clinical development of MICVO as both a monotherapy and in combination with pembrolizumab for the treatment of R/M HNSCC Announced the appointment of Nelson Azoulay as Chief Business Officer         Expected...

Record Quarterly Revenues of $1.04 Billion, a 105% Increase from a Year Ago Excluding Bowers Acquisition, Revenues (non-GAAP) Grew by 57% from a Year Ago1 Quarterly Adjusted EBITDA (non-GAAP) Increased 132% from Prior Year2 Record Total Backlog and Awards of $5.38 Billion, 104% Increase from a Year Ago, with Q1 Book-to-Bill of 1.2x Establish Second Quarter 2026 Guidance for Revenue of $1.05 Billion – $1.1 Billion and Non-GAAP Adjusted EBITDA of $115 Million – $125 Million Raise Full Year 2026 Guidance for Revenue to $4.1 Billion – $4.3 Billion and Non-GAAP Adjusted EBITDA of $470 Million – $490 Million SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) — Legence Corp. (Nasdaq: LGN) (“Legence” or the “Company”) today reported financial results for the first quarter ended March 31, 2026. “Legence delivered a...